BIOATLA, INC. Financing Cash Flow
BIOATLA, INC. (BCAB) reported Financing Cash Flow of $112.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- BIOATLA, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.00K.
- BIOATLA, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $110.00K.
- BIOATLA, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $6.71M, a 27.92% decline year-over-year.
- BIOATLA, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$6.00K.
- BIOATLA, INC. net cash provided by (used in) financing activities for fiscal 2025 was $6.28M, a 34.01% decline from fiscal 2024.
- BIOATLA, INC. net cash provided by (used in) financing activities for fiscal 2024 was $9.51M, a 12251.95% increase from fiscal 2023.
- BIOATLA, INC. net cash provided by (used in) financing activities for fiscal 2023 was $77.00K, a 99.87% decline from fiscal 2022.
- BIOATLA, INC. net cash provided by (used in) financing activities for fiscal 2022 was $61.21M, a 11.94% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $112.00K 10-Q · filed 2026-08-13 | $6.83M derived: sum of 3 quarters · filed 2026-08-13 | $6.82M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $110.00K 10-Q · filed 2026-05-15 | $6.82M derived: sum of 2 quarters · filed 2026-05-15 | $6.82M derived: sum of 3 quarters · filed 2026-05-15 | $6.78M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $6.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $6.71M derived: sum of 2 quarters · filed 2026-03-31 | $6.67M derived: sum of 3 quarters · filed 2026-08-13 | $6.28M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$42.00K derived: sum of 2 quarters · filed 2026-08-13 | -$437.00K 10-Q · filed 2025-11-13 | $8.88M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$431.00K 10-Q · filed 2026-08-13 | $8.88M derived: sum of 3 quarters · filed 2026-08-13 | $8.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$395.00K 10-Q · filed 2026-05-15 | $8.92M derived: sum of 2 quarters · filed 2026-05-15 | $8.90M derived: sum of 3 quarters · filed 2026-05-15 | $9.13M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $9.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $9.30M derived: sum of 2 quarters · filed 2026-03-31 | $9.52M derived: sum of 3 quarters · filed 2026-03-31 | $9.51M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $211.00K derived: sum of 2 quarters · filed 2025-11-13 | $198.00K 10-Q · filed 2025-11-13 | $317.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $225.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $212.00K 10-Q · filed 2025-08-07 | $331.00K derived: sum of 3 quarters · filed 2025-08-07 | $290.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$13.00K 10-Q · filed 2025-05-06 | $106.00K derived: sum of 2 quarters · filed 2025-05-06 | $65.00K derived: sum of 3 quarters · filed 2025-05-06 | $180.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $78.00K derived: sum of 2 quarters · filed 2025-03-28 | $193.00K derived: sum of 3 quarters · filed 2025-03-28 | $77.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | -$41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $74.00K derived: sum of 2 quarters · filed 2024-11-07 | -$42.00K 10-Q · filed 2024-11-07 | $61.72M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $115.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.00K 10-Q · filed 2024-08-08 | $61.76M derived: sum of 3 quarters · filed 2024-08-08 | $61.67M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$116.00K 10-Q · filed 2024-05-14 | $61.65M derived: sum of 2 quarters · filed 2024-05-14 | $61.55M derived: sum of 3 quarters · filed 2024-05-14 | $61.50M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $61.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $61.67M derived: sum of 2 quarters · filed 2024-03-26 | $61.62M derived: sum of 3 quarters · filed 2024-03-26 | $61.21M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$147.00K derived: sum of 2 quarters · filed 2023-11-07 | -$552.00K 10-Q · filed 2023-11-07 | -$4.46M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$456.00K 10-Q · filed 2023-08-01 | -$4.36M derived: sum of 3 quarters · filed 2023-08-01 | $70.78M derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | -$405.00K 10-Q · filed 2023-05-11 | -$4.31M derived: sum of 2 quarters · filed 2023-05-11 | $70.83M derived: sum of 3 quarters · filed 2023-05-11 | $71.02M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $71.23M derived: sum of 2 quarters · filed 2023-03-23 | $71.42M derived: sum of 3 quarters · filed 2023-03-23 | $69.51M 10-K · filed 2023-03-23 |
| 2021-09-30 | $75.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $75.33M derived: sum of 2 quarters · filed 2022-11-04 | $73.42M 10-Q · filed 2022-11-04 | $269.67M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $190.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.72M 10-Q · filed 2022-08-09 | $194.53M derived: sum of 3 quarters · filed 2022-08-09 | $266.67M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$1.91M 10-Q · filed 2022-05-05 | $194.34M derived: sum of 2 quarters · filed 2022-05-05 | $266.48M derived: sum of 3 quarters · filed 2022-05-05 | $269.41M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $196.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $268.39M derived: sum of 2 quarters · filed 2022-02-28 | $271.32M derived: sum of 3 quarters · filed 2022-02-28 | $271.82M 10-K · filed 2022-02-28 |
| 2020-09-30 | $72.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $75.08M derived: sum of 2 quarters · filed 2021-11-15 | $75.58M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $3.43M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $500.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $4.00M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |